PH-790

PH-790 is a small molecule-drug conjugate (SMDC) developed by Philogen S.p.A., designed to deliver a potent Janus kinase 1 and 2 (JAK1/2) inhibitor specifically to the tumor microenvironment. The compound consists of the JAK inhibitor conjugated to OncoFAP, a high-affinity ligand targeting Fibroblast Activation Protein (FAP), which is overexpressed in the stroma of various solid tumors but absent in most healthy tissues. By concentrating the inhibitor at the tumor site, PH-790 aims to block the JAK-STAT signaling pathway—a key driver of tumor proliferation and immune suppression—while reducing the systemic side effects associated with conventional JAK inhibitors. It is currently undergoing Phase I clinical evaluation for the treatment of advanced solid tumors, including clear cell renal cell carcinoma, pancreatic adenocarcinoma, and specific subtypes of colorectal carcinoma (pMMR/MSS/BRAF V600E-negative).

Other names

OncoFAP-JAK inhibitorFAP-targeted JAK1/2 inhibitor